Key points are not available for this paper at this time.
Lifileucel demonstrated durable responses and addresses a major unmet need in patients with metastatic melanoma with limited treatment options after approved therapy, including the primary refractory to anti-PD-1 or PD-L1 therapy subset.
Building similarity graph...
Analyzing shared references across papers
Loading...
Amod A. Sarnaik
Omid Hamid
Nikhil I. Khushalani
Journal of Clinical Oncology
Yale University
University of Minnesota
University of Colorado Denver
Building similarity graph...
Analyzing shared references across papers
Loading...
Sarnaik et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69ed7fd37beaa90d72fab8f5 — DOI: https://doi.org/10.1200/jco.21.00612